Terms: = Head and neck cancer AND BRAF, MGC126806, 673, ENSG00000157764, MGC138284, RAFB1, P15056, B-raf 1, BRAF1, B-raf1 AND Treatment
797 results:
1. Antitumor activity of extracellular signal-regulated kinases 1/2 inhibitor BVD-523 (ulixertinib) on thyroid cancer cells.
Chen Y; Xiao X; Hu G; Liu R; Xue J
J Cancer Res Ther; 2024 Apr; 20(2):570-577. PubMed ID: 38687926
[TBL] [Abstract] [Full Text] [Related]
2. Curcumin Alone and Combined With PI3K Inhibitors Elicits Positive Effects on Oropharyngeal cancer Cell Lines Regardless of HPV Status.
Lukoceviciute M; Zupancic M; Kostopoulou ON; Holzhauser S; Dalianis T
Anticancer Res; 2024 May; 44(5):1863-1876. PubMed ID: 38677772
[TBL] [Abstract] [Full Text] [Related]
3. Decabromodiphenyl ether exposure reduces dabrafenib sensitivity of papillary thyroid carcinoma harboring braf
Wang X; Cui X; Wang Y; Wang Q; Sun F; Liu Z
Toxicology; 2024 May; 504():153807. PubMed ID: 38641160
[TBL] [Abstract] [Full Text] [Related]
4. Integrated proteogenomic and metabolomic characterization of papillary thyroid cancer with different recurrence risks.
Qu N; Chen D; Ma B; Zhang L; Wang Q; Wang Y; Wang H; Ni Z; Wang W; Liao T; Xiang J; Wang Y; Jin S; Xue D; Wu W; Wang Y; Ji Q; He H; Piao HL; Shi R
Nat Commun; 2024 Apr; 15(1):3175. PubMed ID: 38609408
[TBL] [Abstract] [Full Text] [Related]
5. Combined braf and PIM1 inhibitory therapy for papillary thyroid carcinoma based on brafV600E regulation of PIM1: Synergistic effect and metabolic mechanisms.
Xu Q; Wang J; Mao Y; Xuan Z; Yang K; Tang X; Zhu X
Neoplasia; 2024 Jun; 52():100996. PubMed ID: 38593698
[TBL] [Abstract] [Full Text] [Related]
6. Cyto-Histological Profile of MicroRNAs as Diagnostic Biomarkers in Differentiated Thyroid Carcinomas.
Matos ML; Pinto M; Alves M; Canberk S; Gonçalves A; Bugalho MJ; Papoila AL; Soares P
Genes (Basel); 2024 Mar; 15(3):. PubMed ID: 38540448
[TBL] [Abstract] [Full Text] [Related]
7. Advances in targeted therapy and biomarker research in thyroid cancer.
Guo M; Sun Y; Wei Y; Xu J; Zhang C
Front Endocrinol (Lausanne); 2024; 15():1372553. PubMed ID: 38501105
[TBL] [Abstract] [Full Text] [Related]
8. Anaplastic thyroid cancer spheroids as preclinical models to test therapeutics.
Hu J; Liu K; Ghosh C; Khaket TP; Shih H; Kebebew E
J Exp Clin Cancer Res; 2024 Mar; 43(1):85. PubMed ID: 38500204
[TBL] [Abstract] [Full Text] [Related]
9. Progress in long non-coding RNAs as prognostic factors of papillary thyroid carcinoma.
Zhu HN; Song DL; Zhang SN; Zheng ZJ; Chen XY; Jin X
Pathol Res Pract; 2024 Apr; 256():155230. PubMed ID: 38461693
[TBL] [Abstract] [Full Text] [Related]
10. [Intraductal carcinomas of the salivary glands: a clinicopathological and molecular genetic analysis of twenty-seven cases].
Sun Q; Sun JJ; Wang M; Zhang L; Zhang XW; Wei JG; Kong LF; Li J
Zhonghua Bing Li Xue Za Zhi; 2024 Mar; 53(3):250-256. PubMed ID: 38433052
[No Abstract] [Full Text] [Related]
11. Salivary gland carcinoma: Towards a more personalised approach.
Rached L; Saleh K; Casiraghi O; Even C
Cancer Treat Rev; 2024 Mar; 124():102697. PubMed ID: 38401478
[TBL] [Abstract] [Full Text] [Related]
12. A nomogram for predicting adverse pathologic features in low-risk papillary thyroid microcarcinoma.
Gong L; Li P; Liu J; Liu Y; Guo X; Liang W; Lv B; Su P; Liang K
BMC Cancer; 2024 Feb; 24(1):244. PubMed ID: 38389061
[TBL] [Abstract] [Full Text] [Related]
13. CD73 mitigates ZEB1 expression in papillary thyroid carcinoma.
Vedovatto S; Oliveira FD; Pereira LC; Scheffel TB; Beckenkamp LR; Bertoni APS; Wink MR; Lenz G
Cell Commun Signal; 2024 Feb; 22(1):145. PubMed ID: 38388432
[TBL] [Abstract] [Full Text] [Related]
14. Tyrosine kinase inhibitors for radioiodine refractory differentiated thyroid cancer: A systematic review and meta-analysis.
Yu J; Liu Z; Su Y; Peng X; Xie Y
Clin Endocrinol (Oxf); 2024 Apr; 100(4):379-388. PubMed ID: 38351437
[TBL] [Abstract] [Full Text] [Related]
15. A Phase 2 Study of Encorafenib in Combination with Binimetinib in Patients with Metastatic
Tahara M; Kiyota N; Imai H; Takahashi S; Nishiyama A; Tamura S; Shimizu Y; Kadowaki S; Ito KI; Toyoshima M; Hirashima Y; Ueno S; Sugitani I
Thyroid; 2024 Apr; 34(4):467-476. PubMed ID: 38343359
[No Abstract] [Full Text] [Related]
16. Thyroid cancer: A Review.
Boucai L; Zafereo M; Cabanillas ME
JAMA; 2024 Feb; 331(5):425-435. PubMed ID: 38319329
[TBL] [Abstract] [Full Text] [Related]
17. braf V600E Mutation Lacks Association with Poorer Clinical Prognosis in Papillary Thyroid Carcinoma.
Lai HF; Hang JF; Kuo PC; Kuo CS; Yao SF; Chen JY; Lee CH
Ann Surg Oncol; 2024 May; 31(5):3495-3501. PubMed ID: 38300401
[TBL] [Abstract] [Full Text] [Related]
18. Primary Mucosal Melanoma: Clinical Experience from a Single Italian Center.
Falcone R; Verkhovskaia S; Di Pietro FR; Poti G; Samela T; Carbone ML; Morelli MF; Zappalà AR; di Rocco ZC; Morese R; Piesco G; Marchetti P; Failla CM; De Galitiis F
Curr Oncol; 2024 Jan; 31(1):588-597. PubMed ID: 38275835
[TBL] [Abstract] [Full Text] [Related]
19. Identification of a novel genomic variance of braf1 in papillary thyroid carcinoma: A case report.
Wang Y; Zhao J; Tan Z; Du J; Zhang L; Xu Y; Li X; Cai Y; Wang H; Jiang J
Medicine (Baltimore); 2024 Jan; 103(3):e36978. PubMed ID: 38241570
[TBL] [Abstract] [Full Text] [Related]
20. Ubiquitination, SUMOylation, and NEDDylation related genes serve as prognostic and therapeutic biomarkers for oral squamous cell carcinoma.
Deng SZ; Wu X; Kong L; Cheng B; Dai L
J Oral Pathol Med; 2024 Feb; 53(2):114-123. PubMed ID: 38234119
[TBL] [Abstract] [Full Text] [Related]
[Next]
